trending

Hims & Hers Stock Soars After Unexpected Wegovy Partnership with Novo Nordisk

Globexfeed

29 Apr 2025 — 2 min read

Hims & Hers Health is making waves on Wall Street and in the healthcare world after announcing a landmark partnership with Novo Nordisk, the pharmaceutical giant behind the blockbuster weight-loss drug Wegovy. This surprising collaboration has not only redefined telehealth's role in obesity care—it's also catapulted HIMS stock to a record-setting surge of +34.9% in premarket trading.

From Challenger to Partner: A Dramatic Turnaround

Just last year, Hims & Hers carved its place in the telehealth ecosystem by offering compounded alternatives to GLP-1 drugs like Wegovy. It positioned itself as a disruptor—lower-cost, more accessible, and appealing to a market hungry for solutions. But on April 29, 2025, everything changed. The company announced it would now directly sell authentic Wegovy through its platform, thanks to a direct collaboration with Novo Nordisk.

This strategic pivot—from rival to partner—signals a growing appetite among healthcare players to put accessibility above competition. Wegovy, priced through Hims & Hers starting at $599/month, now enters a broader market touchpoint through digital medicine.

Timeline of a Game-Changing Deal

The seeds of this unprecedented alliance were sown in early 2025, when Novo Nordisk slashed Wegovy prices to $499/month via its own NovoCare Pharmacy in March, aiming to increase accessibility. Then came the Hims partnership, sending investors into a frenzy. As analysts and market watchers took note, HIMS stock reached its highest-ever one-day gain—reminiscent of its +31% surge during the explosive early days of the telehealth weight-loss boom in February 2024.

Consumer-Centric Healthcare: A CEO’s Vision

In statements released by Hims & Hers and covered by major outlets like Fox Business, CEO Andrew Dudum shared insights into the company’s motivations behind the partnership:

“We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future.”

The collaboration is framed not just as strategic, but as mission-driven—uniting tech-enabled healthcare with pharmaceutical innovation to make treatments more accessible where it counts most: for everyday people navigating obesity and health challenges.

Emotions Run High: Relief, Irony, and Hope

The move stirred a mix of celebration and surprise within both health circles and the investing community. What makes this story emotionally resonant is the juxtaposition of former competitors now joining forces—and doing so not in quiet, but with the future of weight-loss care at stake. For the average person struggling to afford breakthrough obesity drugs, this partnership spells real, tangible hope.

For investors, it’s a classic underdog story turned blue-chip headline. For patients, it’s the beginning of broader access to a $100B+ weight-loss market previously reserved for the privileged few.